Purpose: We evaluated magnetic resonance imaging controlled transurethral ultrasound therapy as a treatment for magnetic resonance imaging defined focal prostate cancer using subsequent prostatectomy and histology as the reference standard. Materials and Methods: Five men completed this pilot study, which was approved by the institutional review board. Prior to radical prostatectomy focal tumors identified by magnetic resonance imaging were treated by coagulating targeted subtotal 3-dimensional volumes of prostate tissue using magnetic resonance imaging controlled transurethral focused ultrasound. Treatment was performed with a 3 Tesla clinical magnetic resonance imaging unit combined with modified clinical planning software for high intensity focused ultrasound therapy. After prostatectomy whole mount histological sections parallel to the magnetic resonance imaging treatment planes were used to compare magnetic resonance imaging measurements with thermal damage at the cellular level and, thus, evaluate treatment and target accuracy. Results: Three-dimensional target volumes of 4 to 20 cc and with radii up to 35 mm from the urethra were treated successfully. Mean AE SD temperature control accuracy at the target boundary was À1.6 AE 4.8C and the mean spatial targeting accuracy achieved was À1.5 AE 2.8 mm. Mean treatment accuracy with respect to histology was À0.4 AE 1.7 mm with all index tumors falling inside the histological outer limit of thermal injury.
IN men with low to intermediate risk prostate cancer minimally invasive treatments may offer a treatment option for localized disease that is complementary to active surveillance. 1 This represents a middle ground between expectant management and radical treatment. Often delivered to a target or focal region of localized cancer, these treatments aim to destroy a subtotal volume of tissue in the gland, thereby decreasing damage to surrounding sensitive structures.
For this treatment concept to be successful 2 capabilities are required, including 1) accurate localization of cancer in the prostate gland and 2) treatment technologies that can achieve precise targeted tissue destruction in the gland. Multiparametric MRI, which has been shown to provide accurate localization of tumors, could be used to define targets for focal therapy. 2e5 Further, MRIultrasound fusion biopsy systems offer more accurate mapping of cancer in the prostate. 6e8 In an attempt to leverage the strength of MRI for disease localization with the precision of tissue destruction offered by high intensity ultrasound energy we have developed a MRI guided transurethral treatment for localized prostate cancer. The system is MRI compatible and operates in the bore of a clinical scanner to generate a region of thermal ablation in the prostate gland. Real-time proton resonance frequency shift MRI thermometry 9 obtained during therapy is used to achieve accurate spatial control of tissue destruction. In previous phantom, animal and pilot human trials a spatial precision of 2 to 3 mm was demonstrated with good potential for sparing surrounding tissues. Important advantages of this approach compared with transrectal HIFU are decreased treatment time and the ability to treat larger glands. 16 A first in man, treat and resect clinical study performed by Chopra et al demonstrated the feasibility of coagulating prostate tissue using a prototype transurethral system and of monitoring and controlling heating in the prostate during the procedure with MRI thermometry. 12 However, the treatments in this preliminary study did not extend to the periphery of the prostate and only a single plane of tissue was treated. More recently, a phase 1 study using a commercial transurethral system to coagulate the whole prostate gland reported by Chin et al demonstrated an acceptable safety profile and encouraging quality of life outcomes at 12 months. 17 A 3 mm safety margin between the ablation boundary and the prostate capsule was mandated in that series, which left up to 10% of the prostate volume untreated. A related human pilot study has also shown that MRI guided transrectal HIFU ablation is feasible. 18 We describe the performance of a secondgeneration transurethral ultrasound therapy system in humans. To our knowledge this is the first clinical study performed in men prior to radical prostatectomy using a focal approach that combines MRI mapping of the tumor with subtotal prostate ablation. The necessary operating parameters required to achieve the desired therapeutic end point of complete tumor destruction and thermal coagulation up to the prostate capsule were determined, providing an important foundation for future studies with this technology.
MATERIALS AND METHODS

Human Feasibility Study
This clinical study was approved by the Sunnybrook Health Sciences Centre research ethics board. It included men scheduled for radical prostatectomy who had MRI visible, biopsy proven stage T1 or T2a cancer with a Gleason score of 7 or less and PSA less than 15 mg/l. Six men provided informed consent and 5 completed the study.
The study design was a treat and resect clinical investigation to determine the feasibility and safety of coagulating prostate tumors while extending treatment to the prostate boundary. Transurethral treatment was done on the same day as radical prostatectomy with only 1 to 2 hours separating the 2 procedures. All prostatectomies were performed by the same surgeon (LK).
Whole mount hematoxylin and eosin stained histological sections obtained from the prostatectomy specimen were used to evaluate the extent of thermal coagulation and compare this with MRI and thermometry measurements.
Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy System
A prototype transurethral therapy system was integrated into a 3 Tesla Achieva MRI unit (Philips Healthcare, Eindhoven, The Netherlands) for improved spatial resolution and temperature monitoring at the higher field strength. 19 The multi-element transurethral device consisted of 8 contiguous planar transducer elements 5 mm long and 4 mm wide, which could operate independently at 4.5 or 14.5 MHz, or a linear combination of the 2 frequencies.
After the transurethral applicator was inserted in the patient urethra its proximal end was attached to a MRI compatible positioning system affixed to the patient table of the MRI. This system contained a MRI compatible motor that rotated the applicator during treatment to direct energy to specific angular sectors in the gland.
Patients were treated while supine on the MRI patient table. Imaging was performed with a 32 channel cardiac radio frequency coil array (Philips Healthcare). Degassed water was circulated independently through the transurethral applicator and an ECD using a custom-built flow circuit. Figure 1 shows the transurethral applicator, the ECD and a MRI image indicating the positioning of these 2 devices in a patient.
The system was integrated with a modified version of the clinical SonalleveÒ MR-HIFU software platform to facilitate device registration, treatment planning and monitoring. The treatments were intended to achieve complete coagulation of tissue in an angular prostate segment that included the targeted tumor and extended to the capsule. During therapy the software platform dictated acoustic powers, rotation rates and frequencies based on a feedback control algorithm that analyzed temperatures in the prostate gland and along the treatment boundary. 20, 21 In return, the transurethral system transmitted information to the software platform to update the angular position of the device on the display as it rotated during treatment.
Treatment Planning and Delivery
Patients were prepared for treatment on a MRI table outside the magnet room. Spinal anesthesia was administered, and the transurethral transducer and endorectal cooling devices were inserted. The patient bed was transported to and docked into the MRI scanner. Arterial oxygen saturation level, electrocardiogram and blood pressure were monitored throughout treatment using the Expression Model 865214 MRI compatible vital signs monitoring system (Invivo, Gainesville, Florida). Core body temperature was monitored throughout the procedure using a fiberoptic thermometer with a PicoM signal conditioner and an OTG-M3000 sensor (OpSens, Ville de Qu ebec, Quebec, Canada) inserted through a channel in the ECD to ensure contact with the inner rectal wall.
High resolution 2-dimensional T2-weighted images and diffusion-weighted images were used for tumor identification and localization, and treatment planning. The supplementary table (http://jurology.com/) lists the acquisition parameters of the MRI sequences used in the treatment protocol. A target temperature was assigned to target boundaries defined by a uroradiologist (MH) using apparent diffusion coefficient maps with a 5 mm angular extension on either side of the tumor ( fig. 2 ). When the initially chosen target temperature of 54C proved insufficient to produce heating to the prostate boundary, it was increased to 56C and then to 58C in later patients. Treatments used 2 to 6 transducers depending on tumor extent (table 1) .
Treatment was delivered under temperature feedback control designed to maintain a constant temperature at the control boundary by adjusting the individual transducer powers and frequencies as well as the applicator rotation rate. Segmented echo-planar imaging gradient echo thermometry images that were coplanar with the planning images and aligned with the transducers (temporal resolution 6.3 seconds for 10 slices and spatial resolution 1.1 mm) were obtained continuously during the course of treatment. Treatment time ranged from 9 to 35 minutes (table 1) .
Surgery and Correlation with Histology
Open radical prostatectomy using a standard nerve sparing technique was performed immediately following thermal treatment by an experienced prostatectomy surgeon (LK). The excised gland was painted to preserve orientation and paraffin embedded for whole mount histological evaluation. Tissue sections (5 mm) were mounted on slides, stained with hematoxylin and eosin, and digitized.
On each histology image 2 thermal damage boundaries were traced for subsequent comparison with MRI temperature measurements. The boundaries were 1) the outer boundary of ACN, inside of which all cells underwent complete coagulative necrosis, and 2) the OLTI, outside of which there was no visual evidence of thermal damage. Posttreatment analysis included evaluation of the accuracy and precision of heating along the control boundary, treatment accuracy with reference to histology and an estimation of the maximum temperature at which cells were undamaged by treatment. Figure 3 shows axial temperature maps of all treated slices and all cases. This overview indicates that treatments were successful in heating 3D target volumes with a wide variety of shapes, radii and number of slices. In all patients except patient 1 a maximum temperature of 60C to 80C was achieved throughout the planned treatment volume. In patient 1 the fourth active transducer failed, leading to lack of treatment for that slice and poor heating in the adjacent third slice ( fig. 3 ). In patients 2 and 6 under treatment was observed when the sector boundary was close to the edge of the prostate ( fig. 3) , where temperature measurements were unstable due to partial volume effects and the presence of large blood vessels. In patient 4 a region of under treatment coincided with the location of a large calcification, while in the first slices of patients 5 and 6 the presence of large BPH nodules led to uneven patterns of heating ( fig. 3) . Heating outside the planned treatment sector occurred in slice 2 of patient 1, slice 4 of patient 2 and slice 2 of patient 5. This observation could have been caused by heating adjacent muscle or it could have been the result of unreliable thermometry outside the prostate boundary. Table 2 lists mean temperatures and spatial targeting accuracy. For both metrics perfect treatment would be indicated by an accuracy value of 0 with negative values indicating under treatment and positive values indicating overtreatment. In all cases the average temperature at the control boundary was within the error of the target temperature with an overall average of À1.6 AE 4.8C. Overall mean spatial target accuracy was À1.5 AE 2.8 mm.
RESULTS
At radical prostatectomy performed 1 to 2 hours after the procedure tissue consistency was within the normal range. There was no periprostatic adhesion, vascular engorgement or other tissue change that could have been related to prior ultrasound therapy. Figure 4 shows histology images of all 6 treatment planes of patient 6. An irregularly shaped tumor located close to the prostate boundary was present in 5 of the 6 slices. Figure 4 also indicates the ACN and OLTI boundaries. Between these 2 boundaries, which are typically 1 to 2 mm apart, there was some heat induced cell death and enough disruption of tissue structure that complete delayed cell death would have been expected if the prostate had not been removed. 22 The entire tumor was within the OLTI boundary with most of the cancer volume within the smaller ACN boundary. This was true of the index lesions in all 5 cases.
As the temperature of the control boundary (located 2 mm from the capsule) was increased, progressive overtreatment was observed. After the control temperature reached approximately 58C overtreatment reached the prostate capsule, suggesting that this was an appropriate target control temperature. The supplementary figure (http:// jurology.com/) shows the relationship between the amount of overtreatment and the control temperature.
DISCUSSION
This pilot study illustrates the feasibility of coagulating targeted angular sectors completely to the prostate capsule. When averaged over all sector angles, slices and patients, mean temperature control accuracy was À1.6 AE 4.8C while the mean spatial targeting accuracy achieved was 17 The key requirements for this technology to achieve this performance include 1) the ability to plan treatment sectors efficiently on a slice by slice basis, 2) independent control over power and frequency across the multi-element transducer 16, 23 and 3) the capability to perform 3D MRI thermometry with sufficient temporal and spatial resolution to monitor the tissue temperature evolution during treatment. 16, 19, 24, 25 Radical prostatectomy was performed immediately after treatment to assess treatment accuracy, which was the most clinically relevant metric. This was done quantitatively by comparing the cell damage observed in histological sections with temperature maps obtained from MRI thermometry. Average treatment accuracy was À0.4 AE 1.7 mm within an error of zero. The average temperature along the OLTI, ie the maximum temperature at which no significant thermal damage to cells occurred, was 54.0 AE 5.3C. All index tumors were within the outer limit of thermal injury.
Finally, it was observed that when controlling treatment based on MRI thermometry measurements 2 mm inside the prostate capsule, a control temperature of 58C was required to achieve full coagulation out to the boundary of the gland. This requirement for a higher temperature 2 mm inside the prostate gland arises primarily from unreliable proton resonance frequency shift MRI thermometry at the prostate capsule due to a mixed environment of water and fat based tissues.
Although this trial was similar in design to a previous feasibility trial performed by our group, there were major differences in the technology used to generate the treatments. Treatments were performed in a 3 Tesla magnet with full integration into the clinical Sonalleve MR-HIFU treatment planning software. Endorectal cooling was implemented to protect rectal tissues during treatment. A multi-element transducer operating at 2 frequencies was used and multiplanar MRI thermometry was applied to deliver a volumetric treatment. This represents the likely clinical configuration of this technology for whole gland or focal ablation.
There are several limitations to this study. Sample size was small due to the difficulty of recruiting subjects eligible for study and the substantial resource requirements involved in each case (ie 3 hours in the MRI unit followed by 3 hours in the operating room). However, this small sample included prostates with a volume ranging from 31 to 71 cc that contained interesting tissue features such as calcifications and BPH nodules. In the context of this first in man pilot study the treatment parameters evolved during the study in an attempt to determine optimal strategies to coagulate tissue to the prostate boundary.
Anatomical features near and in the prostate can compromise treatment effectiveness. Pulsatile flow in large blood vessels adjacent to the prostate caused erroneous temperature readings, leading to poor temperature control at the target boundary. Blood flow in these extraprostatic vessels may also have a local protective effect against thermal coagulation, as seen from the shape of the ACN boundary in slice 3 of patient 6 ( fig. 4) . Structural inhomogeneities in the prostate, such as calcifications and BPH nodules, can Figure. 4. Histology images of all 6 treatment slices (1 to 6) in patient 6 demonstrate prostate boundary (blue lines), tumor boundary (yellow lines), ACN boundary (white lines) and thermal injury outer limit (black lines). Between ACN boundary and thermal injury outer limit cells may not be immediately destroyed by treatment but are likely to undergo delayed necrosis. Scale bars indicate 2 mm. also lead to uneven heating patterns and failure to treat to the prostate boundary.
CONCLUSIONS
The results of this study demonstrate that MRI guided transurethral ultrasound therapy is capable of generating thermal coagulation in targeted 3D angular sectors in the prostate gland and coagulation can be produced to the prostate capsule in glands up to at least 70 cc. The ultrasound and thermal parameters necessary to achieve this goal were determined in this study and should prove useful for future clinical implementation of this technology.
